Cite
HARVARD Citation
Bruni, C. et al. (2021). Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Therapeutic advances in musculoskeletal disease. p. . [Online].